Clinical Trial Update: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of Modakafusp Alfa (TAK-573) alone and with pembrolizumab in adults with advanced or metastatic solid tumors; the trial was terminated and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Modakafusp Alfa (modakafusp alfa)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D LLC | Conditions: Neoplasms, Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-12-27